See more : EOG Resources, Inc. (0IDR.L) Income Statement Analysis – Financial Results
Complete financial analysis of Capricor Therapeutics, Inc. (CAPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Capricor Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Eniro Group AB (publ) (ENRO-PREF-B.ST) Income Statement Analysis – Financial Results
- Vivid Global Industries Limited (VIVIDIND.BO) Income Statement Analysis – Financial Results
- Kinnevik AB (0RH1.L) Income Statement Analysis – Financial Results
- Dream Industrial Real Estate Investment Trust (DIR-UN.TO) Income Statement Analysis – Financial Results
- BlueFocus Intelligent Communications Group Co., Ltd. (300058.SZ) Income Statement Analysis – Financial Results
Capricor Therapeutics, Inc. (CAPR)
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.18M | 2.55M | 244.90K | 310.25K | 1.01M | 1.67M | 1.37M | 3.19M | 3.78M | 4.79M | 503.23K | 195.50K | 1.35M | 0.00 | 0.00 | 0.00 | 101.40K | 0.00 | 0.00 | 0.00 | 2.18K | 11.48K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.07M | 694.87K | 245.70K | 8.46M | 5.14M | 12.07M | 10.77M | 16.04M | 13.76M | 7.79M | 5.20M | 2.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 24.11M | 1.85M | -799.00 | -8.15M | -4.14M | -10.40M | -9.40M | -12.85M | -9.98M | -3.00M | -4.69M | -2.44M | 1.35M | 0.00 | 0.00 | 0.00 | 101.40K | 0.00 | 0.00 | 0.00 | 2.18K | 11.48K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 95.75% | 72.74% | -0.33% | -2,625.87% | -411.61% | -621.98% | -687.46% | -402.87% | -264.33% | -62.69% | -932.76% | -1,247.43% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 36.45M | 21.82M | 13.57M | 8.46M | 5.14M | 12.07M | 10.77M | 16.04M | 13.76M | 7.79M | 5.20M | 1.02M | 4.14M | 4.08M | 4.47M | 9.48M | 5.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.37M | 10.43M | 7.61M | 5.54M | 3.60M | 4.93M | 4.76M | 4.93M | 4.37M | 3.02M | 2.21M | 1.61M | 2.12M | 2.21M | 3.42M | 3.92M | 4.48M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.43K | 0.00 |
| SG&A | 12.37M | 10.43M | 7.61M | 5.54M | 3.60M | 4.93M | 4.76M | 4.93M | 4.37M | 3.02M | 2.21M | 1.61M | 2.12M | 2.21M | 3.42M | 3.92M | 4.48M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.22K | 10.43K | 0.00 |
| Other Expenses | 0.00 | 190.58K | 548.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 545.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83.00 | 26.09K | 200.00 |
| Operating Expenses | 48.19M | 32.25M | 21.18M | 14.00M | 8.74M | 17.00M | 14.23M | 20.17M | 16.39M | 10.80M | 7.41M | 2.64M | 6.25M | 6.29M | 7.88M | 13.40M | 9.60M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.30K | 36.52K | 200.00 |
| Cost & Expenses | 49.26M | 32.25M | 21.18M | 14.00M | 8.74M | 17.00M | 14.23M | 20.17M | 16.39M | 10.80M | 7.41M | 2.64M | 6.25M | 6.29M | 7.88M | 13.40M | 9.60M | 60.40K | 18.86K | 18.98K | 18.34K | 29.26K | 22.30K | 36.52K | 200.00 |
| Interest Income | 1.73M | 0.00 | 57.46K | 32.94K | 94.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.23K | 6.01K | 20.38K | 47.19K | 332.72K | 287.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 398.81K | 344.67K | 248.63K | 200.51K | 58.13K | 0.00 | 0.00 | 0.00 | 0.00 | 137.00 | 1.09M | 950.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.07M | 694.87K | 245.70K | 143.89K | 171.96K | 157.65K | 144.17K | 134.64K | 110.87K | 41.90K | 26.92K | 6.26K | 7.51K | 12.93K | 159.59K | 113.29K | 26.98K | 0.00 | 0.00 | -900.00 | 0.00 | -2.19K | 83.00 | 200.00 | 200.00 |
| EBITDA | -23.01M | -29.16M | -20.69M | -13.55M | -7.56M | -15.17M | -12.72M | -18.33M | -12.50M | -5.97M | -6.88M | -1.89M | -4.88M | -6.02M | -7.71M | -13.02M | -9.50M | -2.50M | -18.86K | -19.88K | -16.16K | -19.97K | -22.22K | -36.32K | 200.00 |
| EBITDA Ratio | -91.39% | -1,184.21% | -8,700.01% | -4,423.18% | -778.68% | -917.04% | -940.79% | -532.16% | -334.00% | -124.85% | -1,366.36% | -1,244.33% | -361.76% | 0.00% | 0.00% | 0.00% | -9,342.68% | 0.00% | 0.00% | 0.00% | -739.79% | -173.90% | 0.00% | 0.00% | 0.00% |
| Operating Income | -24.08M | -29.70M | -20.94M | -13.69M | -7.73M | -15.33M | -12.86M | -16.98M | -12.61M | -6.02M | -6.90M | -2.44M | -4.90M | -6.29M | -7.88M | -13.40M | -9.50M | -60.40K | -18.86K | -18.98K | -16.16K | -17.78K | -22.30K | -36.52K | -200.00 |
| Operating Income Ratio | -95.63% | -1,165.10% | -8,549.86% | -4,412.56% | -769.52% | -917.04% | -940.79% | -532.16% | -334.00% | -125.72% | -1,371.71% | -1,248.15% | -361.70% | 0.00% | 0.00% | 0.00% | -9,369.29% | 0.00% | 0.00% | 0.00% | -739.79% | -154.82% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.79M | 677.85K | 915.92K | 32.94K | 92.07K | 135.99K | 15.29M | -1.83M | -245.51K | -198.61K | -1.99M | 207.00K | 14.39K | 262.06K | 11.41K | 268.39K | -802.34K | -950.00 | 0.00 | 900.00 | 16.16K | 2.19K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -22.29M | -29.02M | -20.02M | -13.66M | -7.64M | -15.19M | 2.43M | -18.81M | -12.86M | -6.22M | -8.89M | -1.89M | -4.88B | -6.03B | -7.87B | -13.13B | -10.30M | -61.35K | 0.00 | -18.08K | 0.00 | -15.59K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -88.52% | -1,138.50% | -8,175.86% | -4,401.94% | -760.36% | -908.91% | 177.84% | -589.53% | -340.50% | -129.87% | -1,766.96% | -968.31% | -360,633.89% | 0.00% | 0.00% | 0.00% | -10,160.55% | 0.00% | 0.00% | 0.00% | 0.00% | -135.73% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -677.85 | -613.41K | -176.83K | -264.03K | 135.99K | 254.63K | 218.95K | 137.76K | 200.51K | 58.13K | 0.00 | -14.39K | -262.06K | -11.41K | -268.39K | 1.09M | 0.00 | 18.86K | 0.00 | 16.16K | 0.00 | 0.00 | 0.00 | 200.00 |
| Net Income | -22.29M | -29.02M | -19.41M | -13.48M | -7.38M | -15.19M | 2.43M | -18.81M | -12.86M | -6.22M | -8.89M | -1.89M | -4.88M | -6.03M | -7.87M | -13.13M | -10.30M | -61.35K | -18.86K | -18.08K | -16.16K | -15.59K | -22.30K | -36.52K | -200.00 |
| Net Income Ratio | -88.52% | -1,138.48% | -7,925.38% | -4,344.95% | -734.09% | -908.91% | 177.84% | -589.53% | -340.50% | -129.87% | -1,766.96% | -968.31% | -360.63% | 0.00% | 0.00% | 0.00% | -10,160.55% | 0.00% | 0.00% | 0.00% | -739.79% | -135.73% | 0.00% | 0.00% | 0.00% |
| EPS | -0.83 | -1.18 | -0.84 | -0.87 | -1.99 | -5.17 | 1.00 | -10.14 | -8.09 | -5.31 | -8.47 | -1.90 | -65.43 | -93.75 | -154.56 | -272.15 | -304.06 | -2.22 | -12.49 | -11.97 | -10.70 | -10.32 | -14.77 | -26.56 | -0.20 |
| EPS Diluted | -0.83 | -1.18 | -0.84 | -0.87 | -1.99 | -5.17 | 0.90 | -10.14 | -8.09 | -5.31 | -8.47 | -1.90 | -65.43 | -93.75 | -154.56 | -272.15 | -304.06 | -2.22 | -12.49 | -11.97 | -10.70 | -10.32 | -14.77 | -26.56 | -0.20 |
| Weighted Avg Shares Out | 26.78M | 24.55M | 23.09M | 15.57M | 3.71M | 2.94M | 2.32M | 1.86M | 1.59M | 1.17M | 1.05M | 994.52K | 74.66K | 64.34K | 50.93K | 48.25K | 33.88K | 27.59K | 1.51K | 1.51K | 1.51K | 1.51K | 1.51K | 1.38K | 1.00K |
| Weighted Avg Shares Out (Dil) | 26.78M | 24.55M | 23.09M | 15.57M | 3.71M | 2.94M | 2.68M | 1.86M | 1.59M | 1.17M | 1.05M | 994.53K | 74.66K | 64.34K | 50.93K | 48.25K | 33.88K | 27.59K | 1.51K | 1.51K | 1.51K | 1.51K | 1.51K | 1.38K | 1.00K |
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the commencement of a proposed underwritten public offering of shares of...
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
-Data Supports Deramiocel's Sustained Efficacy and Safety in Treating DMD- -Improvements Seen in Multiple Cardiac and Skeletal Endpoints Demonstrating Stabilization of Cardiac and Skeletal Muscle Function Over 3 Years of Treatment- -Company on Track to Fully Submit Biologics License Application...
What Makes Capricor (CAPR) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Capricor (CAPR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA-
Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Capricor (CAPR) points to a 90.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in...
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today that the Company will present the three-year safety and efficacy results...
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary...
Capricor Therapeutics is up over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. NASDAQ: CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its...
Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More
24/7 Wall St. Insights Summer gave way to autumn this past week, and notable insider buying continued.
Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off
BLA submission of deramiocel for treatment of patients with DMD cardiomyopathy is expected in October 2024, with the completed portion expected before the end of 2024. The Duchenne Muscular Dystrophy drugs market size is projected to reach $5.5 billion by...
Source: https://incomestatements.info
Category: Stock Reports